About: Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
Creator	De Mast, Quirijn Buijsers, Baranca Van Der Vlag, Johan Yanginlar, Cansu Maciej-Hulme, Marissa
Source	Elsevier; Medline; PMC
abstract	Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney. Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality in COVID-19. In part, this beneficial effect could be explained by the anticoagulant properties of heparin/LMWH. Here, we summarise potential beneficial, non-anticoagulant mechanisms underlying treatment of COVID-19 patients with heparin/LMWH, which include: (i) Inhibition of heparanase activity, responsible for endothelial leakage; (ii) Neutralisation of chemokines, and cytokines; (iii) Interference with leukocyte trafficking; (iv) Reducing viral cellular entry, and (v) Neutralisation of extracellular cytotoxic histones. Considering the multiple inflammatory and pathogenic mechanisms targeted by heparin/LMWH, it is warranted to conduct clinical studies that evaluate therapeutic doses of heparin/LMWH in COVID-19 patients. In addition, identification of specific heparin-derived sequences that are functional in targeting non-anticoagulant mechanisms may have even higher therapeutic potential for COVID-19 patients, and patients suffering from other inflammatory diseases.
has issue date	2020-08-25(xsd:dateTime)
bibo:doi	10.1016/j.ebiom.2020.102969
bibo:pmid	32853989
has license	no-cc
sha1sum (hex)	46bc3a7409a578414399bd157708740e5e613faf
schema:url	https://doi.org/10.1016/j.ebiom.2020.102969
resource representing a document's title	Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
has PubMed Central identifier	PMC7445140
has PubMed identifier	32853989
schema:publication	EBioMedicine
resource representing a document's body	covid:46bc3a7409a578414399bd157708740e5e613faf#body_text
is schema:about of	named entity 'heparin' named entity 'anticoagulant' named entity 'March 2020' named entity 'D-dimer' named entity 'dengue' named entity 'COVID-19' named entity 'IFN-g' named entity 'leukocyte' named entity 'integrins' named entity 'COVID' named entity 'glycoprotein' named entity 'COVID' named entity 'endothelial' named entity 'ischemia-reperfusion' named entity 'endothelial cells' named entity 'coronaviruses' named entity 'IL-8' named entity 'chemokines' named entity 'anticoagulant' named entity 'anticoagulant' named entity 'chemokines' named entity 'Heparan sulphate' named entity 'antiviral' named entity 'COVID-19' named entity 'COVID' named entity 'LMWH' named entity 'sepsis' named entity 'severe acute respiratory syndrome coronavirus' named entity 'LMWH' named entity 'infection' named entity 'LMWH' named entity 'endothelial cell' named entity 'anticoagulation' named entity 'complement activation' named entity 'thrombosis' named entity 'vaccines' named entity 'endothelial' named entity 'COVID-19' named entity 'microvasculature' named entity 'AKI' named entity 'Vero cells' named entity 'COVID' named entity 'bradykinin' named entity 'anticoagulation' named entity 'heparanase' named entity 'extracellular space' named entity 'blood vessels' named entity 'neutrophil extracellular trap' named entity 'heparin' named entity 'leukocyte' named entity 'bronchial asthma' named entity 'leukocytes' named entity 'LMWH' named entity 'glycocalyx' named entity 'pathogens' named entity 'heparin' named entity 'inflammation' named entity 'clinical studies' named entity 'P-selectin' named entity 'chemical groups' named entity 'proteinuria' named entity 'Neutralisation' named entity 'COVID' named entity 'autopsies' named entity 'histones' named entity 'endothelial' named entity 'apoptosis' named entity 'heparin' named entity 'leaky vasculature' named entity 'AKI' named entity 'glycocalyx' named entity 'preprint' named entity 'NETs' named entity 'heparin' named entity 'selectins' named entity 'SARS-CoV' named entity 'heparin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software